Alto Neuroscience (ANRO) Total Debt (2023 - 2026)

Alto Neuroscience has disclosed Total Debt across 4 years of filings, most recently posting $16.0 million for Q1 2026.

• Total Debt for Q1 2026 came in at $16.0 million, down 19.65% year-over-year; the trailing twelve-month figure through Mar 2026 was $16.0 million (down 19.65% YoY), and the FY2025 annual result was $16.8 million, up 63.42% from the prior year.
• Total Debt came in at $16.0 million for Q1 2026 at Alto Neuroscience, down from $16.8 million in the prior quarter.
• In the past five years, Total Debt ranged from a high of $20.3 million in Q3 2025 to a low of $9.9 million in Q4 2023.
• The 4-year median for Total Debt is $13.1 million (2024), against an average of $14.3 million.
• Across the five-year window, Total Debt jumped 100.22% in 2025 and dropped 19.65% in 2026, its largest moves.
• Alto Neuroscience's Total Debt stood at $9.9 million in 2023, then climbed by 3.99% to $10.3 million in 2024, then jumped by 63.42% to $16.8 million in 2025, then fell by 4.39% to $16.0 million in 2026.
• The last three Total Debt figures came in at $16.0 million (Q1 2026), $16.8 million (Q4 2025), and $20.3 million (Q3 2025), per Business Quant data.